Brinzolamide clinical trials
Also written Azopt.
How each study uses brinzolamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 1 Apr 1998 · AZOPT · NDA 020816 (FDA, Drugs@FDA)
- European Union
- 9 Mar 2000 · Azopt · EMEA/H/C/000267 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2011 (10)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 10 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 4
Alcon Research (30) · Bausch & Lomb Incorporated (2) · Padagis LLC (1) · Novartis Pharmaceuticals (1) · Alcon, a Novartis Company (1) · Akron Children's Hospital (1) · Northwestern Ophthalmic Institute S.C. (1) · Hermann Eye Center (1)
Often tested with
Tested in the same studies.
Travoprost (4) · Dorzolamide (3) · Brimonidine (3) · Timolol (2) · Latanoprost (2) · Levobetaxolol hydrochloride (1) · Levobetaxolol (1) · Dorzolamide-timolol combination (1)
Studies
Open first, then newest update. How each study uses brinzolamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Stop Retinal Ganglion Cell Dysfunction StudyTerminatedPhase 3University of MiamiNCT02390284Written as Brinzolamide
- Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptCompletedPhase 3Bausch & Lomb IncorporatedNCT01722604Written as brinzolamide 1% ophthalmic suspension
- Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptCompletedPhase 1/2Bausch & Lomb IncorporatedNCT03896633Written as brinzolamide 1% ophthalmic suspension
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both EyesCompletedPhase 3Padagis LLCNCT04024072Written as Brinzolamide 1% ophthalmic suspension
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®TerminatedPhase 4Alcon ResearchNCT02730871Written as Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
- Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension GlaucomaCompletedPhase 4Novartis PharmaceuticalsNCT03150160Written as brinzolamide 1%/brimonidine 0.2% fixed combination
- SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)CompletedPhase 4Alcon ResearchNCT02419508Written as Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
- 24-hr Intraocular Pressure Control With SIMBRINZA ®CompletedPhase 4Alcon ResearchNCT02770248Written as Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
- Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedPhase 3Alcon ResearchNCT02339584Written as Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension
- Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic SolutionCompletedPhase 4Alcon, a Novartis CompanyNCT02325518Written as Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
- Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionCompletedPhase 4Alcon ResearchNCT00372827Written as Brinzolamide 1% added to Travoprost 0.004%
- A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Alcon ResearchNCT00326092Written as Brinzolamide/Timolol
- IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive TherapyCompletedPhase 4Alcon ResearchNCT00382226Written as Azopt
- A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Alcon ResearchNCT00314158Written as Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
- Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedPhase 3Alcon ResearchNCT00061516Written as AZOPT (brinzolamide)
- Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular HypertensionCompletedPhase 4Alcon ResearchNCT00300079Written as brinzolamide 1.0%
- A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Alcon ResearchNCT00314171Written as Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
- Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueCompletedPhase 4Alcon ResearchNCT01937312Written as Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
- Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®CompletedPhase 4Alcon ResearchNCT01937299Written as Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
- Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 4Alcon ResearchNCT01978600Written as Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension
See all 40 studies that test brinzolamide →
As the comparator · 6 — what is tested is compared with brinzolamide
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Sun Pharmaceutical Industries LimitedNCT05022004Written as Azopt®
- 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Alcon ResearchNCT02140060Written as Brinzolamide 1% ophthalmic suspension AZOPT®
- Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPTTerminatedPhase 3Alcon ResearchNCT00767494Written as Azopt
- Argon Laser Peripheral Iridoplasty for Primary Angle Closure GlaucomaStatus unknownPhase 3Singapore National Eye CentreNCT00980473Written as Travatan/ Timolol/Azopt
- Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure GlaucomaStatus unknownPhase 3Singapore Eye Research InstituteNCT01004900Written as Travoprost/ Timolol/ Azopt/ Brimonidine
- Efficacy Comparison of Xalatan and Azopt on POAG and OHStatus unknownNot applicablePeking University First HospitalNCT01084902Written as Brinzolamide
Codes
What other systems call brinzolamide · ClinicalTrials.gg INT004067
- MeSH (NLM) C111827brinzolamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9451Z89515BRINZOLAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 194881Confirmed FDA, Wikidata
- Wikidata Q411517brinzolamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47420BrinzolamideOne source FDA
- DrugBank DB01194One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C111827 | brinzolamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9451Z89515 | BRINZOLAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 194881 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411517 | brinzolamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47420 | Brinzolamide | One source FDA |
| DrugBank | DB01194 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.